247 related articles for article (PubMed ID: 24621095)
1. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Li Y; Li S; Zhu Y; Liang X; Meng H; Chen J; Zhang D; Guo H; Shi B
J Clin Hypertens (Greenwich); 2014 Mar; 16(3):177-85. PubMed ID: 24621095
[TBL] [Abstract][Full Text] [Related]
2. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients.
Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
Am J Ther; 2017; 24(1):e81-e101. PubMed ID: 26322676
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
4. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
[TBL] [Abstract][Full Text] [Related]
5. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.
Fishman MN; Tomshine J; Fulp WJ; Foreman PK
PLoS One; 2015; 10(4):e0120877. PubMed ID: 25830512
[TBL] [Abstract][Full Text] [Related]
7. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
10. The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
Zheng Y; Wang F; Wu G; Zhang L; Wang Y; Wang Z; Chen P; Wang Q; Lu J; Wang Y; Li P; Wang J; Lu X; Yuan J
Medicine (Baltimore); 2015 Dec; 94(49):e2222. PubMed ID: 26656362
[TBL] [Abstract][Full Text] [Related]
11. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
Yang X; Pan X; Cheng X; Cheng Y; Kuang Y
Int J Clin Pharm; 2015 Dec; 37(6):1047-56. PubMed ID: 26173936
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
13. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
Kim SH; Kim S; Nam BH; Lee SE; Kim CS; Seo IY; Kim TN; Hong SH; Kwon TG; Seo SI; Joo KJ; Song K; Kwak C; Chung J
PLoS One; 2015; 10(8):e0135165. PubMed ID: 26308612
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
16. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Rini BI; Quinn DI; Baum M; Wood LS; Tarazi J; Rosbrook B; Arruda LS; Cisar L; Roberts WG; Kim S; Motzer RJ
Target Oncol; 2015 Mar; 10(1):45-53. PubMed ID: 24595903
[TBL] [Abstract][Full Text] [Related]
17. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
20. Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; Santoni M; de Cobelli O; Nolé F
Crit Rev Oncol Hematol; 2016 Mar; 99():324-31. PubMed ID: 26818051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
